Time is of the essence when progressing hits to leads and on to preclinical candidates of drug discovery & development. Swift access to ADME-Tox / in vivo PK data is indispensable for expediting the design-make-test cycle.
We support also projects in need for time-critical early ADME characterization. Our expertise lies in swiftly providing essential information tailored to your project’s needs, with the right assays conducted at the right time. Whether as part of an integrated drug discovery program with Symeres or as a standalone service within the Admescope platform, we’re dedicated to bringing efficiencies to your drug discovery journey.
As a standalone early in vitro ADME screening, we have automatized assays ensuring obtaining fast and accurate data for solubility, logD, metabolic stability, PPB and CYP inhibition. For frequently occurring screenings, the data is available within a week!
As part of integrated drug discovery projects at Symeres, our suite of early in vitro ADME assays offers comprehensive insights crucial for the medicinal chemistry teams. These include tests governing physicochemical characteristics, metabolic and chemical stability evaluations, permeability assessments (such as PAMPA, Caco2, or MDCK-MDR1 screening), along with plasma protein binding studies, coupled with preliminary in vivo pharmacokinetic screening in our AAALAC accredited animal unit.
Beyond early ADME, our extensive portfolio extends to cover the entire spectrum of non-clinical in vitro ADME-Tox and in vivo DMPK assays. Regardless of your project’s stage, our capabilities stand ready to provide dedicated support covering all drug modalities.
Get in touch with our team to discuss more into our capabilities or to request a quote.
Frequently Asked Questions
Early ADME data provide critical insight into the absorption, distribution, metabolism, and excretion properties of drug candidates during hit-to-lead and lead optimization stages. Rapid access to these data can help accelerate design-make-test cycles, support compound prioritization, and enable informed decision-making throughout drug discovery.
Admescope offers automated early ADME screening services including solubility, logD, metabolic stability, plasma protein binding (PPB), and CYP inhibition assays. Additional studies can include permeability assessments and preliminary in vivo pharmacokinetic screening.
For frequently requested screening assays, Admescope can provide data within one week. These automated workflows are designed to deliver fast, reliable ADME information for time-critical drug discovery projects.
Early ADME data provide medicinal chemistry teams with rapid feedback on physicochemical properties, metabolic stability, permeability, and protein binding. These insights help prioritize compounds, guide optimization efforts, and accelerate design-make-test cycles.
Admescope offers permeability assessments including PAMPA, Caco-2, and MDCK-MDR1 screening assays. These studies help evaluate compound permeability and support early understanding of absorption characteristics.
Yes. Early ADME programs can be complemented by preliminary in vivo pharmacokinetic screening performed within Admescope’s AAALAC-accredited animal facility, providing additional insight into compound behavior in vivo.
Yes. Early ADME services can be delivered as part of integrated drug discovery programs through Symeres, combining medicinal chemistry, ADME-Tox, and DMPK expertise to support efficient project progression.
Yes. Admescope’s early ADME capabilities support projects across a wide range of drug modalities and can be delivered as standalone studies or as part of integrated drug discovery programs. The broader Admescope portfolio also provides access to non-clinical in vitro ADME-Tox and in vivo DMPK services throughout drug discovery and development.
